EVFM OTC
Evofem Biosciences, Inc.
1W: -3.9%
1M: -7.5%
3M: -22.1%
YTD: -22.1%
1Y: -44.8%
3Y: -94.7%
5Y: -100.0%
$0.01
+0.00 (+10.81%)
Weekly Expected Move ±7.8%
$0
$0
$0
$0
$0
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Income Trends
Revenue
$20M
+4.2% ▲
5Y CAGR: +114.4%
Gross Profit
$15M
-3.0% ▼
Operating Income
$1M
+118.7% ▲
Net Income
$391K
+104.4% ▲
EPS (Diluted)
$0.00
+100.0% ▲
EBITDA
$2M
+129.8% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $8M | $17M | $18M | $19M | $20M |
| YoY Growth | +1748.4% | +104.2% | +8.2% | +6.3% | +4.2% |
| Cost of Revenue | $4M | $4M | $7M | $4M | $5M |
| Gross Profit | $4M | $12M | $12M | $16M | $15M |
| Gross Margin | 50.8% | 73.8% | 64.3% | 80.2% | 74.7% |
| R&D Expenses | $33M | $25M | $3M | $2M | $3M |
| SG&A Expenses | $138M | $72M | $27M | $21M | $17M |
| Operating Expenses | $171M | $97M | $30M | $23M | $14M |
| Operating Income | -$167M | -$84M | -$18M | -$8M | $1M |
| Operating Margin | -2023.3% | -499.6% | -98.0% | -39.6% | 7.1% |
| Interest Expense | $0 | $0 | $0 | $0 | $3M |
| Income Before Tax | -$205M | -$77M | $53M | -$9M | $393K |
| Tax Expense | $17K | $44K | $17K | $0 | $2K |
| Net Income | -$205M | -$77M | $53M | -$9M | $391K |
| Net Margin | -2489.0% | -455.5% | 290.8% | -45.8% | 1.9% |
| EPS (Diluted) | $-2962.49 | $-164.59 | $0.05 | $-0.09 | $0.00 |
| EBITDA | -$166M | -$82M | -$16M | -$7M | $2M |
| Shares Outstanding | 69818 | 465984 | 984M | 96M | 6.42B |